The number of persons with gender incongruence seeking gender affirming hormonal treatment with sex hormones is increasing in Denmark. Gender affirming therapy of transgender men most often includes testosterone treatment (TT). Testosterone is an important anabolic and androgenic hormone. During treatment testosterone is increased around 20 fold. Testosterone is an important anabolic and androgenic hormone.
Aim: To investigate how TT affects quality of life, cardiovascular health, respiratory function, body composition and muscle strength in transgender men in relation to age at transition, pre-existing cardiovascular risk factors and conditions and the dosage of hormones administered.
Methods: A prospective 10 year cohort study of 200 transgender men (+18 years). Persons included undergo examinations before initiation of TT and after 1, 3, 5 and 10 years of TT.
All examinations are performed with state of the art methods and the themes of the study program are:
- Quality of life
- Cardiovascular risk and function
- Respiratory function
- Body composition and muscle strength Ethics and dissemination: The study is approved by the regional ethics committee (S-20190108) and the Danish Data Protection Agency. The results of this study will be disseminated in peer-reviewed journals.
